| Literature DB >> 35326031 |
Tapas Ranjan Padhi1, Utpal Bhusal1, Srikanta Kumar Padhy1, Anamika Patel1, Anup Kelgaonker1, Ashish Khalsa1, Taraprasad Das2, Vidushi Kapil1, Miloni Shah1, Shalini Sugumar1, Balakrushna Samantaray3, Sabita Devi4, Mohammad Hasnat Ali5, Subhadra Jalali2.
Abstract
Purpose: To analyze the weekly rate of retinal vascular growth in treatment-naïve babies with various stages of retinopathy of prematurity (ROP) and validate if this could be a predictor of treatment need.Entities:
Keywords: Intravitreal bevacizumab; retinal vascular growth; retinopathy of prematurity; treatment
Mesh:
Substances:
Year: 2022 PMID: 35326031 PMCID: PMC9240487 DOI: 10.4103/ijo.IJO_1484_21
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 2.969
Figure 1(Left) Color fundus image of the left eye taken with 3netra neo digital wide-field imaging system (Forus Health Pvt. Ltd) showing few tortuous vascular loops around the optic disc. Nasally, they hardly extend beyond 1.5 DD from the nasal border of the optic disc. (Right) Same eye after red-green enhancement making the blood vessels stand out with better clarity
Figure 2Snapshot image showing the method of measurement of vascular growth done on the laptop screen and the caliper option available with RetCam (Clarity Medical Inc.). The eye shown here shows threshold retinopathy of prematurity (ROP) in zone I. The disc dimensions are measured both horizontally and vertically, and the ends of the blood vessels are measured in supero, infero, and horizontal temporal quadrants
Speed of vascular out growth in eyes with treatable, low risk prethreshold and no ROP
| Groups (251 babies, 436 eyes) | Description | STQ ( | ITQ ( | HTQ ( | SNQ ( | INQ ( | HNQ ( | All Quadrantstogether |
|---|---|---|---|---|---|---|---|---|
| Group 1 | ||||||||
| All | Treatable ROP | 0.522±0.136 (236) | 0.514±0.131 (232) | 0.475±0.149 (191) | 0.373±0.113 (20) | 0.315±0.103 (17) | 0.227±0.099 (22) | 0.490±0.121 |
| 1A | Threshold ROP (37 babies, 64 eyes) | 0.480±0.101 (63) | 0.475±0.091 (64) | 0.444±0.114 (52) | 0.301±0.267 (02) | 0.233±0.165 (2) | 0.107 (1) | 0.461±0.123 |
| 1B | APROP (31 babies, 59 eyes) | 0.432±0.104 (59) | 0.427±0.111 (57) | 0.343±0.095 (40) | 0.384±0.115 (12) | 0.326±0.104 (10) | 0.224±0.094 (16) | 0.386±0.104 |
| 1C | HybridROP (16 babies, 28 eyes) | 0.538±0.132 (28) | 0.512±0.126 (26) | 0.461±0.142 (23) | 0.363±0.067 (4) | 0.329±0.083 (4) | 0.247±0.126 (4) | 0.480±0.112 |
| 1D | HRPTHROP (52 babies, 87 eyes) | 0.610±0.124 (86) | 0.602±0.118 (85) | 0.571±0.132 (76) | 0.4±0.043 (02) | 0.306 (01) | 0.328 (01) | 0.592±0.069 |
| Group 2 (64 babies, 108 eyes) | Low risk prethreshold ROP | 0.632±0.105 (105) | 0.613±0.104 (96) | 0.589±0.108 (97) | - | - | - | 0.612±0.106 |
| Group 3, (51 babies, 90 eyes) | NOROP | 0.721±0.090 (87) | 0.705±0.093 (51) | 0.731±0.097 (57) | - | - | - | 0.719±0.093 |
APROP-Aggressive Posterior ROP, HNQ-Horizontal nasal quadrant, INQ-Inferonasal quadrant, HRPTH ROP-High Risk Prethreshold Retinopathy of Prematurity, HTQ-Horizontal temporal quadrant, ROP-Retinopathy of Prematurity, SNQ- Superonasal quadrant, STQ- Superotemporal quadrant
Figure 3Collage of representative fundus images from different groups and subgroups analyzed in the present study. (a) Right eye showing threshold Retinopathy of prematurity (ROP) in zone II posterior. (b) Right eye of a case with aggressive posterior retinopathy of prematurity (APROP). (c) Case of hybrid ROP showing features of both APROP and staged ROP in the same eye. (d) Left eye showing stage 3 zone II plus ROP (high risk pre threshold). (e) Right eye showing stage 2 Zone II pre plus (low risk pre threshold) ROP. (f) Zone III Immature retina, no ROP in the right eye
Gestational age (GA), birth weight (BW), and postmenstrual age (PMA) at the calculation of babies within three subgroups in the present study
| Parameters | Treatable ROP as a whole (Gr 1) | Subgroup 1A (Threshold) | Subgroup 1B (APROP) | Subgroup 1C (Hybrid) | Subgroup 1D (HRPTH) | Low risk pre threshold ROP (Gr 2) | NO ROP (Gr 3) |
|---|---|---|---|---|---|---|---|
| GA in weeks | 23-36 | 25.28-34 | 26.71-34 | 28.29-35 | 23-36 | 25-38 | 29-38 |
| (Range, Avg±SD) | 30.091±1.97 | 29.72±1.98 | 30.07±1.48 | 30.95±2.09 | 30.089±2.098 | 30.60±2.03 | 32.44±2.17 |
| BW in g | 640-2100 | 640-1900 | 850-1700 | 1000-1900 | 840-2100 | 700-2500 | 900-2400 |
| (Range, Avg±SD) | 1261.61±292.56 | 1218.98±290.57 | 1210.33±205.11 | 1319.28±265.71 | 1309.19±305.85 | 1432.33±363.69 | 1634.54±324.45 |
| PMA in weeks at calculation | 29-44.57 | 34-43.57 | 31-41.71 | 33-39.14 | 29-44.57 | 31-45.97 | 32.85-41 |
| (Range, Avg±SD) | 36.52±2.37 | 37.92±2.29 | 35.06±2.14 | 35.74±2.13 | 36.73±3.02 | 38.65±2.92 | 37.49±1.72 |
ROP-Retinopathy of Prematurity, SD-Standard deviation, Postmenstrual age is defined as a sum of gestational age and number of days elapsed since birth
Interobserver correlation coefficient between observers 1 and 2
| Treatment Required | STQ | ITQ | HTQ | |||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Interobserver correlation | 95% Confidence interval | Interobserver correlation | 95% Confidence interval | Interobserver correlation | 95% Confidence interval | |
| Single measures | 0.9664 | 0.9593-0.9722 | 0.7789 | 0.7128-0.8282 | 0.7804 | 0.7261-0.8231 |
| Average measures | 0.9829 | 0.9792-0.9859 | 0.8757 | 0.8323-0.9060 | 0.8767 | 0.8413-0.9030 |
HTQ-Horizontal temporal quadrant; ITQ-Inferotemporal quadrant; STQ-Superotemporal quadrant Values less than 0.5 are indicative of poor reliability, values between 0.5 and 0.75 indicate moderate reliability, values between 0.75 and 0.9 indicate good reliability, and values greater than 0.90 indicate excellent reliability
Figure 4Diagram showing the average speed of retinal vascularization in babies with retinopathy of prematurity of varying severity
Receiver operating characteristic curve of STQ, ITQ, and HTQ for predicting requirement of treatment
| Treatment Required | STQ | ITQ | HTQ |
|---|---|---|---|
| Area under the ROC curve (AUC) | 0.817 | 0.791 | 0.819 |
| Standard Error | 0.0202 | 0.0232 | 0.0229 |
| 95% Confidence interval | 0.777-0.853 | 0.747-0.831 | 0.774-0.858 |
|
| <0.0001 | <0.0001 | <0.0001 |
| Cutoff | ≤0.569 | ≤0.578 | ≤0.542 |
| Sensitivity (95% CI) | 66.95% (60.6-72.9%) | 73.71% (67.5-79.3%) | 67.37% (60.2-74.0%) |
| Specificity (95% CI) | 82.29% (76.1-87.4%) | 71.23% (63.2-78.4%) | 83.66% (76.8-89.1%) |
| PPV (95% CI) | 82.3% (76.1-87.4%) | 80.3% (74.3-85.4%) | 83.7% (76.8-89.1%) |
| NPV (95% CI) | 66.9% (60.6-72.9%) | 63% (55.2-70.4%) | 67.4% (60.2-74.0%) |
| Diagnostic accuracy | 73.83% | 72.75% | 74.63% |
CI-Confidence interval; HTQ-Horizontal temporal quadrant; ITQ-Inferotemporal quadrant; NPV-Negative predictive value, PPV-Positive Predictive Value, ROC-Receiver Operating Characteristic curve; STQ-Superotemporal quadrant
Figure 5The receiver operating characteristic curve (ROC) to find out the area under the curve and cutoff point of vascular growth in superotemporal quadrant (STQ), inferotemporal quadrant (ITQ), and horizontal temporal quadrant (HTQ) for predicting the requirement of treatment. ROC curves above the diagonal line are considered to have a reasonable discriminating ability to predict the requirement of treatment. The discriminatory power of the rate of vascular growth (area under curve: 0.819, 0.791, and 0.819; 95% confidence interval: 66.95, 73.71, and 63.37, respectively, for STQ, ITQ, and HTQ) was acceptable. The rate of vascular growth was a significant predictor of the requirement of treatment at a cutoff value of ≤ 0.569 (STQ), ≤0.57 (ITQ), and ≤ 0.542 (HTQ) with a chance of correctly predicting the requirement of treatment in 81%, 79%, and 81% of the cases, respectively